2. Search Result
Search Result
Results for "

Medullary

" in MedChemExpress (MCE) Product Catalog:

17

Inhibitors & Agonists

2

Peptides

1

Inhibitory Antibodies

1

Recombinant Proteins

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-101246
    RPI-1

    		RET Cancer
    RPI-1 is a specific, orally available 2-indolinone Ret tyrosine kinase inhibitor. RPI-1 inhibits proliferation, Ret tyrosine phosphorylation, Ret protein expression, and the activation of PLCgamma, ERKs and AKT in human medullary thyroid carcinoma TT cells. Antitumor activity .
    RPI-1
  • HY-W009776
    Suberoyl bis-hydroxamic acid

    Suberohydroxamic acid; SBHA

    		 HDAC Apoptosis Cancer
    Suberoyl bis-hydroxamic acid (Suberohydroxamic acid; SBHA) is a competitive and cell-permeable HDAC1 and HDAC3 inhibitor with ID50 values of 0.25 μM and 0.30 μM, respectively .Suberoyl bis-hydroxamic acid renders MM cells susceptible to apoptosis and facilitates the mitochondrial apoptotic pathways .Suberoyl bis-hydroxamic acid can be used for the study of medullary thyroid carcinoma (MTC) .
    Suberoyl bis-hydroxamic acid
  • HY-Y1876
    Guaiacol Carbonate

    		Others Others
    Guaiacol Carbonate acts as an expectorant by virtue of a reflex from the stomach by way of the afferent gastric nerves to the medullary centres and thenperipherally again to the respiratory tract .
    Guaiacol Carbonate
  • HY-108585A
    VU591

    		Potassium Channel Neurological Disease
    VU591 is a potent, selective renal outer medullary potassium channel (ROMK or Kir1.1) inhibitor, with an IC50 of 0.24 μM. VU591 can be used for neurological research with HY-108585 (the equivalent of VU591 hydrochloride) .
    VU591
  • HY-156113
    RET-IN-25

    		RET Cancer
    RET-IN-25 (compound 6b) is a RET kinase inhibitor with anticancer activity. RET-IN-25 inhibits medullary thyroid carcinoma (MTC) with IC50s of 3.6 μM (3 days) and 3.0 μM (6 days) against TT(C634R) MTC .
    RET-IN-25
  • HY-132201
    MK-8153

    		Potassium Channel Metabolic Disease
    MK-8153 is a potent, selective and orally active inhibitor of renal outer medullary potassium channel (ROMK), with IC50s of 5 nM, 34 μM for ROMK electrophysiology (EP) and hERG EP, respectively. MK-8153 can be used as the diuretic/atriuretic .
    MK-8153
  • HY-143546
    RET-IN-9

    		RET Cancer
    RET-IN-9 is a potent inhibitor of RET. RET kinase is a single-pass transmembrane receptor tyrosine kinase that plays an important role in the development of the kidney and enteric nervous system, and the maintenance of homeostasis in the nervous, endocrine, hematopoietic, and male reproductive systems. RET-IN-9 has the potential for the research of RET-related disease including non-small cell lung cancer and medullary thyroid cancer (extracted from patent WO2021115457A1, compound 29) .
    RET-IN-9
  • HY-P1403
    Tertiapin LQ

    		Potassium Channel Others
    Tertiapin LQ is a specific and reversible renal outer medullary potassium ROMK1 (Kir1.1) channel inhibitor .
    Tertiapin LQ
  • HY-124687
    ROMK-IN-32

    		Potassium Channel Cardiovascular Disease
    ROMK-IN-32 is a renal outer medullary potassium channel (ROMK) inhibitor with an IC50 of 35 nM. ROMK-IN-32 also inhibits hERG with an IC50 of 22 μM .
    ROMK-IN-32
  • HY-162555
    BMS-986308

    		Potassium Channel Cardiovascular Disease
    BMS-986308 is a selective and orally active renal outer medullary potassium (ROMK) channel inhibitor. BMS-986308 is selective for ROMK over hERG. BMS-986308 can be used for heart failure research .
    BMS-986308
  • HY-108585
    VU591 hydrochloride

    		Potassium Channel Neurological Disease
    VU591 hydrochloride is a potent, selective renal outer medullary potassium channel (ROMK or Kir1.1) inhibitor, with an IC50 of 0.24 μM. VU591 hydrochloride can be used for neurological research with HY-108585A (the equivalent of VU591 hydrochloride) .
    VU591 hydrochloride
  • HY-156135
    NSC194598

    		RET Others
    NSC194598 is a p53 DNA-binding inhibitor with IC50 value of 180 nM and 2-40 μM for in vitro and in vivo, respectively. NSC194598 interferes with transcriptional activation of mutated RET gene in human medullary thyroid carcinoma TT cells. NSC194598 can be used for acute toxicity to normal tissues by radiation and chemotherapy research .
    NSC194598
  • HY-122282
    AZ11657312

    		Others Cardiovascular Disease
    AZ11657312 is a P2X7 receptor antagonist with activity to restore stress natriuresis. AZ11657312 significantly increased renal medullary perfusion, only in mice treated with angiotensin II. AZ11657312 improves tissue oxygenation by blocking P2X7R, especially in areas of the kidney that are underoxygenated. Administration of AZ11657312 increased sodium excretion up to sixfold while normalizing blood pressure .
    AZ11657312
  • HY-124944
    APS6-45

    		Ras Cancer
    APS6-45 is an orally active tumor-calibrated inhibitor (TCI). APS6-45 inhibits RAS/MAPK signaling and exhibits antitumor activity .
    APS6-45
  • HY-121667
    Scaff10-8

    		ROCK Cancer
    Scaff10-8, bound to RhoA, inhibits the AKAP-Lbc-mediated RhoA activation .
    Scaff10-8
  • HY-108595
    VU590

    		Potassium Channel Others
    VU590 is a potent and moderately selective ROMK (Kir1.1) inhibitor, with an IC50 of 290 nM. VU590 also inhibits Kir7.1, with an IC50 of 8 μM. VU590 is not a good probe of ROMK function in the kidney .
    VU590
  • HY-110076
    VU590 dihydrochloride

    		Potassium Channel Others
    VU590 dihydrochloride is a potent and moderately selective ROMK (Kir1.1) inhibitor, with an IC50 of 290 nM. VU590 also inhibits Kir7.1, with an IC50 of 8 μM. VU590 dihydrochloride is not a good probe of ROMK function in the kidney .
    VU590 dihydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: